NeuroSense Therapeutics Ltd. (NRSN)
NASDAQ: NRSN · IEX Real-Time Price · USD
1.260
-0.080 (-5.97%)
At close: Apr 25, 2024, 4:00 PM
1.280
+0.020 (1.59%)
After-hours: Apr 25, 2024, 5:44 PM EDT
NeuroSense Therapeutics Market Cap
NeuroSense Therapeutics has a market cap or net worth of $21.84 million as of April 25, 2024. Its market cap has increased by 3.51% in one year.
Market Cap
21.84M
Enterprise Value
19.27M
1-Year Change
3.51%
Ranking
Category
Stock Price
$1.26
Market Cap Chart
Since the IPO on December 9, 2021, NeuroSense Therapeutics's market cap has decreased from $64.61M to $21.84M, a decrease of -66.20%. That is a compound annual growth rate of -36.66%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Apr 24, 2024 | 20.60M | -1.44% |
| Apr 23, 2024 | 20.90M | 0.48% |
| Apr 22, 2024 | 20.80M | -4.59% |
| Apr 19, 2024 | 21.80M | -6.84% |
| Apr 18, 2024 | 23.40M | -4.88% |
| Apr 17, 2024 | 24.60M | -3.15% |
| Apr 16, 2024 | 25.40M | 8.09% |
| Apr 15, 2024 | 23.50M | -4.47% |
| Apr 12, 2024 | 24.60M | -4.65% |
| Apr 11, 2024 | 25.80M | 1.18% |
| Apr 10, 2024 | 25.50M | -3.77% |
| Apr 9, 2024 | 26.50M | -1.12% |
| Apr 8, 2024 | 26.80M | 2.68% |
| Apr 5, 2024 | 26.10M | -17.67% |
| Apr 4, 2024 | 31.70M | 23.83% |
| Apr 3, 2024 | 25.60M | 11.79% |
| Apr 2, 2024 | 22.90M | 0.44% |
| Apr 1, 2024 | 22.80M | 0.44% |
| Mar 28, 2024 | 22.70M | 5.09% |
| Mar 27, 2024 | 21.60M | 1.89% |
| Mar 26, 2024 | 21.20M | -6.61% |
| Mar 25, 2024 | 22.70M | 3.65% |
| Mar 22, 2024 | 21.90M | -3.10% |
| Mar 21, 2024 | 22.60M | 8.65% |
| Mar 20, 2024 | 20.80M | 13.04% |
View and export this data all the way back to 2021.
Sign Up Today.
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| CytoMed Therapeutics | 24.79M |
| Movano | 24.60M |
| Enlivex Therapeutics | 24.54M |
| Exagen | 24.13M |
| Cue Health | 23.78M |
| Cumberland Pharmaceuticals | 23.25M |
| Aptorum Group | 22.94M |
| Biora Therapeutics | 22.93M |